Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Microglial SWELL1 deficiency drives male-specific seizure vulnerability but paradoxical neuroprotection through impaired phagocytosis
Abhijeet S. Barath, Aastha Dheer, Laura Montier, Mekenzie M Peshoff, Emily Dale, Flavia Goche, Thanh Thanh Le Nguyen, Mastura Akter, FangFang Qi, Dimitrios Kleidonas, Lauren Harris, Sarah A. Jewanee, Anthony D. Umpierre, Dale B. Bosco, Koichiro Haruwaka, Rajan Sah, Long-Jun Wu
Abhijeet S. Barath, Aastha Dheer, Laura Montier, Mekenzie M Peshoff, Emily Dale, Flavia Goche, Thanh Thanh Le Nguyen, Mastura Akter, FangFang Qi, Dimitrios Kleidonas, Lauren Harris, Sarah A. Jewanee, Anthony D. Umpierre, Dale B. Bosco, Koichiro Haruwaka, Rajan Sah, Long-Jun Wu
View: Text | PDF
Research Article Immunology Neuroscience

Microglial SWELL1 deficiency drives male-specific seizure vulnerability but paradoxical neuroprotection through impaired phagocytosis

  • Text
  • PDF
Abstract

The discovery of genes encoding the volume-regulated anion channel (VRAC) has enabled detailed exploration of its cell type–specific roles in the brain. LRRC8A (SWELL1) is the essential VRAC subunit. We observed seizure-induced, subunit-specific changes in microglial VRAC expression and investigated its function using conditional KO (cKO) of LRRC8A in microglia. SWELL1 cKO mice exhibited a male-specific increase in kainate-induced seizure severity, yet showed paradoxical neuroprotection against seizure-associated neuronal loss. Mechanistically, SWELL1 deletion led to a cell-autonomous reduction in microglial density and decreased release of VRAC-permeable neuroactive metabolites, including taurine, GABA, and glutamate in culture. Additionally, impaired phagocytic kinetics and reduced lysosomal biogenesis contributed to the observed neuroprotection. These findings reveal potentially novel roles for microglial VRAC in regulating seizure outcomes and microglia-neuron interactions.

Authors

Abhijeet S. Barath, Aastha Dheer, Laura Montier, Mekenzie M Peshoff, Emily Dale, Flavia Goche, Thanh Thanh Le Nguyen, Mastura Akter, FangFang Qi, Dimitrios Kleidonas, Lauren Harris, Sarah A. Jewanee, Anthony D. Umpierre, Dale B. Bosco, Koichiro Haruwaka, Rajan Sah, Long-Jun Wu

×

Figure 4

SWELL1 deletion confers paradoxical neuroprotection after seizures due to reduced lysosomal biogenesis.

Options: View larger image (or click on image) Download as PowerPoint
SWELL1 deletion confers paradoxical neuroprotection after seizures due t...
(A) Nissl staining showing neuronal loss in CA3 pyramidal layer at day 3 after seizure (arrowheads, pyknotic nuclei; 4–11 animals/group examined). Scale bar: 50 μm. (B) Immunofluorescence images showing neuronal loss and myeloid and CD68 responses in CA3 at day 3 after seizure (10–11 animals/group examined). Scale bar: 50 μm. (C) Quantification of Nissl-positive cell bodies at baseline and day 3 after seizure (statistic: unpaired t test). (D) Quantification of relative NeuN-positive area in CA3 at baseline and day 3 after seizure (statistic: unpaired 2-tailed t test). (E) Quantification of myeloid cell density in CA3 pyramidal layer at day 3 after seizure (statistic: unpaired 2-tailed t test). (F) Distribution and average of nearest neighbor distances for myeloid cells in CA3 pyramidal layer (statistic: Mann-Whitney U test and 2-way ANOVA). (G) 3D reconstructed and orthogonal views of NeuN-CD68 volumetric interactions in CA3 pyramidal layer (zoomed-in view of regions of interest [ROIs] shown B). Scale bar: 10 μm. (H) Quantification of CD68+ area in CA3 at baseline and day 3 after seizures (statistic: unpaired t test). (I) Quantification of mean CD68 granule sizes at day 3 after seizures. (J and K) Quantification of NeuN-CD68 double-positive voxels in CA3 pyramidal layer (statistic: Mann-Whitney U test). (L) Correlation between CD68+ and NeuN+ area in CA3 pyramidal layer at day 3 after seizure (statistic: Pearson’s correlation coefficient). (M) 3D reconstructed and orthogonal views of Iba1-CD68 volumetric interactions in CA3 pyramidal layer (zoomed-in view of ROIs shown in B). Scale bar: 10 μm. (N and O) Quantification of Iba1-CD68 double-positive voxels in CA3 pyramidal layer (statistic: unpaired 2-tailed t test). (P) Correlation between Iba1+ and CD68+ area in CA3 pyramidal layer at day 3 after seizure (statistic: Pearson’s correlation coefficient, r; simple linear regression to compare the slopes). *P <0.05, **P <0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts